Ferroptosis
Inhibitory Selectivity
Ferroptosis Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S7243 |
Ferrostatin-1 (Fer-1)Ferrostatin-1 (Fer-1) is a potent and selective inhibitor of ferroptosis with EC50 of 60 nM. |
Indicated HCC cells were treated with sorafenib (5 µM) and erastin (10 µM) with or without cell death inhibitors (ferrostatin-1, 1 µM; liprostatin-1, 100nM; ZVAD-FMK,10 µM; necrosulfonamide, 0.5 µM) for 24 hours and cell viability was assayed (n=3, *p < 0.05 versus sorafenib or erastin treatment group).
|
|
| S7699 |
Liproxstatin-1Liproxstatin-1 is a potent ferroptosis inhibitor with an IC50 of 22 nM. |
(a-d) Liproxstatin-1 treatment, given immediately after reperfusion, attenuated motor function decline measured by rotarod (a), progressive neurological deficits (b), n =8, final infarct volumes (c, right) and cognitive function decline (d). Representative TTC-stained serial brain sections 24 h after MCAO/reperfusion are shown in (c, left), scale bar=1 cm.
|
|
| S8792New |
UAMC-3203UAMC-3203 is an improved ferroptosis inhibitor with an IC50 value of 10 nM in IMR-32 neuroblastoma cells. |
||
| S7242 |
ErastinErastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS. |
PANC1 and PANC2.03 cells were treated with staurosporine or erastin (D) in the absence or presence of indicated cell death inhibitors for 24 hours. Cell viability was assayed (n = 3, *P < 0.05).
|
|
| S8254 |
FIN56FIN56 is a specific inducer of ferroptosis . |
||
| S8155 |
RSL3RSL3 is a ferroptosis activator in a VDAC-independent manner,exhibiting selectivity for tumor cells bearing oncogenic RAS. RSL3 binds, inactivates GPX4 and thus mediates GPX4-regulated ferroptosis. |
Fluvastatin treatment of HT-1080 cells decreases GPX4 protein levels in a time- and concentration-dependent manner and synergized with co-treatment with the direct GPX4 inhibitor RSL3.
|
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S7243 |
Ferrostatin-1 (Fer-1)Ferrostatin-1 (Fer-1) is a potent and selective inhibitor of ferroptosis with EC50 of 60 nM. |
Indicated HCC cells were treated with sorafenib (5 µM) and erastin (10 µM) with or without cell death inhibitors (ferrostatin-1, 1 µM; liprostatin-1, 100nM; ZVAD-FMK,10 µM; necrosulfonamide, 0.5 µM) for 24 hours and cell viability was assayed (n=3, *p < 0.05 versus sorafenib or erastin treatment group).
|
|
| S7699 |
Liproxstatin-1Liproxstatin-1 is a potent ferroptosis inhibitor with an IC50 of 22 nM. |
(a-d) Liproxstatin-1 treatment, given immediately after reperfusion, attenuated motor function decline measured by rotarod (a), progressive neurological deficits (b), n =8, final infarct volumes (c, right) and cognitive function decline (d). Representative TTC-stained serial brain sections 24 h after MCAO/reperfusion are shown in (c, left), scale bar=1 cm.
|
|
| S8792New |
UAMC-3203UAMC-3203 is an improved ferroptosis inhibitor with an IC50 value of 10 nM in IMR-32 neuroblastoma cells. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S7242 |
ErastinErastin is a ferroptosis activator by acting on mitochondrial VDAC, exhibiting selectivity for tumor cells bearing oncogenic RAS. |
PANC1 and PANC2.03 cells were treated with staurosporine or erastin (D) in the absence or presence of indicated cell death inhibitors for 24 hours. Cell viability was assayed (n = 3, *P < 0.05).
|
|
| S8254 |
FIN56FIN56 is a specific inducer of ferroptosis . |
||
| S8155 |
RSL3RSL3 is a ferroptosis activator in a VDAC-independent manner,exhibiting selectivity for tumor cells bearing oncogenic RAS. RSL3 binds, inactivates GPX4 and thus mediates GPX4-regulated ferroptosis. |
Fluvastatin treatment of HT-1080 cells decreases GPX4 protein levels in a time- and concentration-dependent manner and synergized with co-treatment with the direct GPX4 inhibitor RSL3.
|
